Clinical Study Of Sorafenib For Patients With Advanced Renal Cell Carcinoma

Objective To evaluate the safety and efficacy of sorafenib for patients with advanced stage renal cell carcinoma. Methods The clinical data of 85 patients with advanced renal cell carcinoma from 2006.1 to 2009.5 were reviewed. These patients were treated by sorafenib 400mg Bid,800mg Bid or sorafenib 400mg Bid sorafenib in combination with interferon-a-2b, respectively, until intolerable or disease progression occurred. The primary end points were the overall rate of objective response, disease control rate and adverse effects rate. These data were analyzed through SPSS 13.0.Results The data of 80 patients can be evaluated. The median follow-up duration was 72 weeks (4-108 weeks). CR (1.25%,1/80), PR (21.3%,17/16), SD (62.5%,50/80), PD (15 %,12/80). The overall rate of objective response and disease control rate were 22.53% (CR+PR)and 83.3%(CR+PR+SD), respectively. By 2009.5, only 18 patients were dead, PES and OS were not available. The common side effects included:hand-foot skin reaction (51.8%), mucus hemorrhage (49.4%), diarrhea(37.6%), lassitude(32.9%), anorexia(21.2%), mucus ulcer (18.8%), hypertension(14.1%) and baldness(14.1%) et. Most of these side effects can be released by treatments. Conclusions Sorafenib has good short term curative effect for patients with advanced renal cell carcinoma. The common side effects include:hand-foot skin reaction, mucus hemorrhage, diarrhea, hypertension and baldness et, most of these side effects are 1-2 grade, patients have good tolerance for sorafenib. PFS and OS can not be available by now.